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DRUG USERS’ BELIEFS ON MANDATORY NEWBORN HIV TESTING IN THE STATE OF
CONNECTICUT. Odicie O. Fielder, John Hodges, and Frederick Altice. Section of Internal
Medicine, Yale University School of Medicine, New Haven, CT.
We examined health beliefs among drug users about mandatory HIV testing of newborns
and voluntary versus mandatory testing of pregnant women. We also examined to what extent
negative experiences and stigmatization affect attitudes towards HIV testing.
Baseline structured interviews of active drug users from 1997-2001 were examined.
Multivariate data analysis was performed using SAS statistical software. Subsequently, five
distinct focus groups were conducted in September 2003. Focus groups were transcribed, coded
and analyzed using Microsoft Word 2000.
Of 610 drug users interviewed, nearly all (89%) had been previously HIV tested. Nearly
all (91%) subjects believed pregnant women should be tested for HIV. More subjects who had
prior HIV testing believed all pregnant women should be HIV tested (92.9% vs. 82.6%, p=0.008).
Though 86% of subjects agreed with testing of all newborns, only 57% of all subjects believed
that this should be mandatory. Among women, however, more injectors than non-injectors would
avoid prenatal care if HIV testing was required during pregnancy (16.2% vs. 6.1%, p<0.01). Of
the 499 subjects reporting a usual site for care, 31.8% believed that “certain types of people”
received better treatment than others. Not using drugs, being of a certain race/ethnicity, and
having private insurance were associated with receiving better care. Perceived discrimination by
the healthcare system was also cited as a barrier to acceptance of testing strategies. In the focus
groups, arguments against mandatory testing of pregnant women included the loss of choice,
right not to know HIV status, and the belief that mandatory testing was both a means of provoking
rebellion and promoting discrimination. Concern for the baby’s health was the primary reason for
supporting mandatory newborn testing.
The current practice of mandatory newborn and voluntary prenatal screening for HIV in
Connecticut appears to have been acceptable to a population of stigmatized drug users with or at
risk for HIV. Despite acceptance, perceived discrimination by the healthcare system persists and
may result in adverse outcomes for drug using men and women.
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I. INTRODUCTION
Pediatric acquired immunodeficiency syndrome (AIDS) is now a chronic
disease, with those infected now living well into adulthood. As a result of an
evolving epidemic, most pediatric AIDS results from maternal to child
transmission (MTCT). Through many policy changes and laws, states such as
Connecticut have aggressively sought ways to eradicate perinatal transmission.
Despite advances in both antiretroviral and obstetrical interventions, perinatal
human immunodeficiency virus (HIV) transmission continues to occur in the
United States. MTCT occurs largely due to missed opportunities for prevention,
namely among women who are not receiving prenatal care (1) or are not being
tested during prenatal care (2). In addition, suboptimal use of antiretroviral
medications in HIV-infected pregnant women continues to allow for transmission
to occur.
In 1994, the AIDS Clinical Trials Study Group 076 (PACTG 076)
published the results of their randomized, double-blind, placebo-controlled trial
designed to test the efficacy of zidovudine (AZT) in decreasing vertical
transmission of HIV. The HIV positive women in the treatment arm had received
oral AZT throughout their pregnancy. In addition, AZT was given intravenously
during the labor and infants were started at birth on oral drug to complete six
weeks of therapy. The results of this trial demonstrated that zidovudine (AZT)
reduced vertical transmission from 25% to 8% (3). Studies by the International
Perinatal HIV group later proved that Caesarean section could reduce
transmission by 50% (4). With the implementation of these regimens, by the
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1992 (5). Despite these advances, the Centers for Disease Control (CDC)
estimates that between 280 and 370 infants continue to be born with HIV
infection each year in the U.S. (6)
Since the CDC’s initial issuance of guidelines, much debate has occurred
over developing policies to most effectively reduce MTCT. In addition, many
revisions to policies have occurred. Although HIV/AIDS appeared globally in the
early 1980’s, the development of a coordinated governmental policy response
would be years in the making. The initial casting of the epidemic was as one
affecting gay white men predominantly. Nearly a decade passed before the
government acknowledged the high rates of HIV infection in mostly poor and
minority women and children. As a response to the PACTG 076 results, the
CDC issued guidelines in 1995 stating that pregnant, HIV-infected women should
be offered antiretroviral therapy. Specifically, these guidelines promoted
voluntary counseling and testing. Outside the health care arena, in 1996
Congress’ attention was gained, leading to reauthorization of the Ryan White
Comprehensive AIDS Resources (CARE) Act of 1990. This legislation gave
funds to states, hospitals, and cities with high numbers of AIDS cases to provide
treatment and support for persons living with the disease. The 1996 amendments
represented the first time Congress had addressed MTCT. The new requirement
was such that all states were admonished to adopt the CDC’s guidelines for HIV
counseling and voluntary testing for pregnant women. States were penalized
such that by failing to adopt these guidelines, they risked loss of funding. To
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requested that the National Academy of Science conduct a study of state
compliance.
Stemming from the congressionally commissioned study, the Institute of
Medicine (IOM) issued a report in 1999 recommending “that the United States
adopt a policy of universal HIV testing with patient notification, as a routine
component of prenatal care”. Universal testing means that all pregnant women
will be offered testing, regardless of risk status. Under routine testing, a woman is
told that HIV testing will be performed with a battery of prenatal screening tests
unless she specifically declines (7). As women are not explicitly asked to accept
testing, this is also known as the opt-out approach. This policy is in contrast to
both voluntary testing (where an individual must explicitly accept the offer of an
HIV test with written consent required or recommended) and mandatory testing
(which carries no option for refusing a test). Voluntary testing is also known as
the opt-in consent approach. Previously, the IOM supported universal HIV
counseling and voluntary testing. The continued occurrence of pediatric HIV
cases in the face of this policy, however, prompted a revision of their position
statement.
Though implementation of new state and federal guidelines led to an
increase in HIV testing, the goal of testing all pregnant women had not been met
by the year 2000. This then prompted the CDC to revise it’s recommendations
for HIV counseling and testing of pregnant women in the year 2000. The main
change in the new guidelines was the decreased emphasis on pretest counseling
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advocate the voluntary, ‘opt-in’ consent process (8). With much progress to be
made before eradication of infection of newborns, the CDC continued to seek
more aggressive ways to combat MTCT. The advent of rapid HIV testing, which
could be used to screen women in labor and allow them to begin intrapartum
antiretroviral therapy, provided another avenue to support screening women at
delivery. In a November 2002 Morbidity and Mortality Weekly Report publication,
the CDC examined the different HIV testing approaches (9). Here they found
that the highest rates of maternal testing were being achieved with ‘opt-out’
testing. As a result of this, in 2003, CDC adopted the initiative, New Strategies
for a Changing Epidemic, for the first time promoting an opt-out approach to HIV
testing of pregnant women (10). As the government sought to maximize efforts to
reduce MTCT, medical professional organizations issued position statements
and recommendations to guide health care practitioners. Although these
statements are not mandates to health workers, they are widely used in
determining the “standard of care” for members practicing in those fields. Of all
the organizations, the American College of Obstetricians and Gynecologists
(ACOG) was the most aggressive in it’s efforts. Specifically, ACOG
recommended “implementation of universal testing with notification and the right
to refuse”. (Press Release, American College of Obstetricians and
Gynecologists, HIV Tests Urged for All Pregnant Women: Ob-Gyns Launch
Campaign for Universal HIV Screening, at http://www.acog.org/from
home/publications/press releases/nr05-23-00-2.cfm. May 23, 2000).
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American Academy of Pediatrics and the American Medical Association issued
statements advocating pretest counseling of pregnant women with an ‘opt-in’
consent process. Of note, none of the professional organizations advocated
mandatory testing for pregnant women (11). In 1999, the state of Connecticut
implemented legislation requiring providers to inform patients that HIV testing
would be part of routine prenatal care. It was required that such notification be
given twice during the pregnancy. If there was no available evidence of prior
testing at delivery, the mother would be informed that HIV testing would be done
unless she specifically objected in writing. Faced with initial opposition (12),
rates of maternal testing in the state increased from 31 to 81% after
implementation of the new law (13,14). Success of this policy is illustrated in the
fact that in the year 2000, all infants born to HIV-infected mothers in the state’s
capitol tested negative (City of Hartford Health Department, HIV/AIDS
Surveillance Report, January 2002). Routine testing has certainly led to improved
rates of HIV testing among pregnant women (15,16). In addition, studies have
demonstrated that routine testing is cost-effective and improves detection of HIV
in community (17) and correctional settings (18).
Other states have responded to the success of routine and voluntary
testing. A survey in 2002 found that 17 states in the US had statutes regarding
prenatal HIV testing. The remaining states used general HIV testing laws for the
rest of the population and applied them to pregnant women, or had some other
policy to guide prevention of maternal-to-child transmission. Of the seventeen
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testing strategy for pregnant women. The remaining six had statutes based on
routine, opt out testing (19). The remaining states had various policies that in
some way addressed perinatal HIV transmission.
Along with testing pregnant women, newborn HIV testing with subsequent
treatment presents another option in reducing maternal-to-child transmission.
Abbreviated AZT regimens begun in the intrapartum period or in the first 48
hours of newborn life have also reduced the rate of MTCT. This has created a
safety net for cases missed by prenatal screening (20). As of 2002, only four
states had addressed newborn HIV testing. In Indiana, physicians may test
newborns if deemed medically necessary. There is no legal requirement of the
physician to test, though testing may be performed without parental consent (21).
The provision does, however, state that the mother must be notified that testing
has been done. In Rhode Island, informed consent for HIV testing is not required
of anyone less than one year of age (22). New York State, with its history of
disproportionately high rates of births to HIV infected women, was the first to
adopt a mandatory HIV screening law for newborns in 1996 (23). Connecticut
passed a similar law in 1999, requiring testing of all newborns without record of
maternal testing during pregnancy or delivery, in the absence of parental
consent. The other component of this law with respect to testing of pregnant
women has been previously mentioned in this article. There have been
challenges to acceptance of these laws as well. In essence, a woman who did
not learn her HIV status during her entire pregnancy would be subjected to that
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objections. Disapprobation of this law was primarily based on the idea that
women would be forced to learn their HIV status, thus being no different from a
mandatory testing law of pregnant women.
Opponents of mandatory newborn testing have also cited ethical
concerns. The most salient of these are an individual’s basic right to privacy and,
more specific to the medical field, informed consent. Much of the subtleties in the
different testing strategies proposed by the IOM and the CDC have differed in the
manner in which informed consent was addressed. The issue has been raised as
to whether Connecticut and New York’s laws represent a form of coercion by
effectively presenting a threat of an unwanted action to the baby unless the
mother takes a test. Lending credence to this idea, a study of prenatal patients in
Connecticut found that some women would accept testing in order to keep their
babies from being tested (24).
In addition, debates over risk/benefit balance in screening tests (such as
HIV) have raised ethical concerns. By definition, screening tests assess healthy
individuals whom are not seeking medical attention for the condition being
screened. In considering HIV, it is known that early diagnosis and treatment
prolongs survival. For many diseases, opponents argue that the cost, injury and
stigmatization a patient may incur by testing positive for a test may not justify the
risk (25). What effect a positive test may have on the individual’s experience of
stigmatization and injury continues to evolve with the epidemic. Others remain
opposed to mandatory HIV testing based on the notion that if a pregnant women
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avoid prenatal care altogether. This is of particular concern with respect to
women who are drug users, as these groups have historically been shown to
have lower rates of attending prenatal care (26).
There are special considerations when considering routine or mandatory
testing among pregnant women who use illicit drugs. In comparison to the
general U.S. population, drug users are more likely to experience preventable
acute illness, insufficient medical management of chronic illness, or lack of
access to appropriate care (27). Drug users have been shown to be more likely
to avoid health care treatment than compared with non-drug users (28). Even
when health care is obtained, this group has also been demonstrated to be less
satisfied with access to the healthcare system than the general population (29).
Compounding the issue of drug use with those of living with HIV/AIDS in this
society, one would expect that there are still barriers towards HIV testing in the
nation. Self perceived risk can serve as both a motivating (23) and deterring
factor to obtaining HIV testing. Considerations of these issues are required when
discussing HIV testing in this population. Drug using women may not seek
knowledge of HIV status after weighing the consequences of revealing status to
partners or child protection agencies (30). In addition, historical mistrust of the
medical system by marginalized groups of society continues to affect
participation in health care (31,32).
In understanding the complex history between physicians and drug users,
it is appropriate to consider how drug use, specifically opiate addiction, emerged
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century physician with vast public health and psychiatric training. He was known
throughout much of his later career for his psychiatric explanation of addiction
and advocacy for medical rather than judicial handling of such people. At the
same time, he also led credence to the ideas of distinguishing “accidental”
medical addicts from willful ones (33). These ideas provided much of the
framework for the common day issues of drug users and their relationships with
health care.

II. STATEMENT OF PURPOSE, HYPOTHESIS AND SPECIFIC
AIMS
Connecticut’s laws on HIV testing of pregnant women and newborns
continue to be met with reprehension. Initial concern was based primarily on the
fear that disenfranchised groups would avoid prenatal care as a direct result of
knowledge of these laws. Though previous studies have addressed drug users’
motives for HIV testing, none have adequately studied the acceptability of both
routine prenatal testing for pregnant women and mandatory testing of newborns.
As rates of newborn HIV testing have continued to decline, we hypothesized that
despite initial concern, drug using men and women in Connecticut do not
find the laws on testing unacceptable. The purpose of this study is, 1) to
understand the attitudes and beliefs of a group affected by the current laws, the
drug using patient population, and, 2) to specifically address the issue of
avoidance of prenatal care secondary to implementation of these laws.
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III. METHODS
Both quantitative and qualitative methods were used in two different arms
of this study. Structured interviews from two longitudinal studies of drug users
(DU’s) with subsequent qualitative methods using focus groups were used to
obtain insights into drug users’ knowledge and attitudes on mandatory HIV
screening policies for newborns.
Quantitative Longitudinal Cohort Studies.

The first arm of this study,

which consisted of surveys, was conducted prior to the introduction of the current
author to the project. These were conducted prior to and around the time of
implementation of mandatory newborn testing in Connecticut. From 1997-1999,
Project CHEER (Community, Health Education, Evaluation and Research) was
conducted by a group of researchers affiliated with Yale AIDS Program. Project
CHEER consisted of 373 out of treatment injection drug users (IDU’s). The
second cohort, Project 2000, was comprised of 234 out of treatment non-injecting
drug users (NIDU’s). These NIDU’s were recruited from 1999 to 2000 at various
drug treatment centers in and around New Haven. Both were recruited using
respondent driven sampling, often used to recruit representative samples of
difficult to reach populations (34). The cohort of IDU’s has been previously
described (35,36 ). After informed consent was obtained, each participant was
administered a standardized questionnaire with questions regarding
demographics, drug use, health services utilization, sexual behavior, and
psychological well being. In 2003, the initial survey data was revisited to assess

- 11 attitudes regarding HIV testing of pregnant women and newborns. The current
author extracted the following queries:
1) Do you think pregnant women should be required to be tested for HIV?
2) Do you think all newborns should be required to be tested for HIV?
and
3) If there was a law that required all pregnant women to get an HIV test,
would you avoid seeing a provider for prenatal care to avoid taking the test?

Multivariate statistical analyses were performed with SAS statistical software,
version 8.0 (SAS Institute, Cary, NC, U.S.A). 1
Qualitative Focus Group Study. After an initial analysis of the data to examine
the range of attitudes regarding mandatory HIV testing, a qualitative approach
was introduced. Approval for the study was obtained from the Yale School of
Medicine Human Investigation Committee. As we were particularly interested in
the responses of HIV-infected, drug using women, we recruited two distinct
groups: one comprised of IDU’s and the other NIDU’s. In September 2003,
focus groups were conducted with a sum total of 25 HIV-infected and uninfected,
drug using men and women. Five groups were conducted in total: one consisted
of five HIV positive men, one with five HIV positive/ injection drug using women,
one with five HIV positive non-injection drug using women, one with five HIV
negative women, and one with five HIV negative women. The rationale for
separating groups according to sex and serostatus was to maintain homogeneity
and capitalize on people’s shared experiences and attributes. Males were
1

Performed by Carol Chelimo, BS, MPH at Yale AIDS Program.
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involved in a woman’s decision to access prenatal care and/or obtain an HIV test.
Similar to the two longitudinal cohorts, individuals were eligible if they
were over the age of 18 and had a history of cocaine or heroin use within the
previous six months. Exclusion criteria included non-English speakers and those
unable to provide informed consent. Subjects were recruited by staff from
various clinical drug treatment and community based outreach sites in New
Haven. Each focus group was held at the site from which the participants were
recruited. Identities were anonymous, with codes (double letter initials) used for
reference during the interview and transcription. Informed consent was obtained
from each participant in the group setting. Focus groups covered four thematic
areas: 1) knowledge of HIV transmission, 2) attitudes towards voluntary versus
mandatory testing of pregnant women and newborns 3) HIV testing and
counseling experiences, and 4) stigma and trust of the medical institution. Each
taped focus group session lasted approximately 90 minutes. Participants were
provided lunch and paid $25 at the conclusion of each session. The male focus
groups were moderated by two researchers, one male (John Hodges, coauthor)
and one female (Odicie Fielder, author). All groups containing women were
conducted by the author. All groups were taped and transcribed by the same
author. Transcripts were analyzed multiple times to identify and code broad
themes. Once themes were identified, anecdotal elements were isolated by
theme and gender using Microsoft Word.
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IV. RESULTS
Quantitative Longitudinal Cohort Studies
Tables 1 through 5 are derived from the 610 original participants in the two
longitudinal cohort studies. For Table 3, the data set was limited to the 586
(96%) of the 610 subjects who had undergone prior HIV testing. Tables 4 and 5
are limited to the 499 (82%) of subjects who reported having had a usual place of
health care. Data from these tables may therefore not equal the total sample
size stated at the top of the table due to missing data.
Table 1 displays selected baseline demographic and drug use
characteristics of the 610 (376 IDU and 234 NIDU) study participants. The mean
age was 38.7 years and 66.6% were non-white. Of all drug users, 238 (39.0%)
were women. Nearly all subjects (88.7%) had been previously tested for HIV, of
which 26% reported being HIV-infected.
Table 2 shows attitudes on mandatory testing of newborns and pregnant
women with respect to drug use history (injection versus non-injection). The
majority of subjects reported that pregnant women should undergo HIV testing.
With regard to testing newborns for HIV, 56.7 % (N= 337) felt that they should be
tested without the mother’s consent, which would constitute mandatory testing.
Nearly 14% of subjects did not support testing of newborns. None of these
values were statistically significant. There were no differences between IDU’s
and NIDU’s with regard to those beliefs. Among the 238 women surveyed,
however, more IDU’s would avoid prenatal care than NIDU’s (16.2% vs. 6.1 %,
p<0.01) if HIV testing was mandatory during pregnancy.
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newborns stratified by history of previous HIV testing. Subjects who had been
tested for HIV in the past were significantly more likely to believe that pregnant
women should undergo HIV testing (92.9% v. 82.6 %, p <0.01). There were no
statistically significant differences between all subjects who had and had not
been tested for HIV in the past with regards to newborn testing and willingness to
participate in prenatal care among women.
We examined experiences with and attitudes towards health care in the
longitudinal cohorts. Of the 610 participants, 499 (82%) participants reported a
usual place of health care that included specialty clinics, mental health care,
community vans, and prisons. Of these, 173 (31.8 %) believed that certain
people at their site received better treatment than others. Of participants who
agreed with this statement, women were nearly 40 percent less likely than their
male counterparts to agree with this statement, {AOR = 0.61; 95% CI(0.41-0.93)}
In addition, having tested positive for HIV was associated with believing that
certain people receive better care services. {AOR = 0.42; 95% CI (0.25-0.72)}
(Table 4). In table 5, we examined the health care experiences and attitudes
among those engaged in care. Types of people whom these participants felt
received better care included those who didn’t use drugs (74%), those of a
particular race/ethnicity (70%) and those who had private insurance (68%). In
general, participants harbored negative feelings about the healthcare
environment related to it’s attitude toward drug users. Drug users were found to
have negative experience with the healthcare system because their symptoms
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use (74%).
Qualitative Focus Group Analysis
Focus group information was used to provide further clarification of the
responses from the longitudinal cohort data. Direct excerpts were extracted into
the following three categories: 1) attitudes toward testing of pregnant women; 2)
attitudes towards testing in newborns and attitudes toward prenatal care; 3)
healthcare experiences and attitudes.

Attitudes Toward Testing of Pregnant Women:
When discussing HIV testing of pregnant women, male and female
participants were asked,

Would you be more likely to get an HIV test if I told you: As a pregnant
woman, it is required that you have an HIV test or, As a pregnant woman, it is the
law that you undergo an HIV test?

Nearly all participants, regardless of HIV status or gender, disagreed with
mandating HIV testing by law. The primary and most frequent objection to this
method was fear of a loss of autonomy and choice. Participants also cited a
woman’s right to not know her HIV status as an important reason for being
against mandatory testing. Voluntary testing, with the implicit right to consent,
was the preferred method for administering HIV testing. G.X., an HIV negative
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implementation of the routine testing laws.

GX: I have 8 children. So whenever we go, you know for
prenatal or whatever, that’s one thing that they definitely do.
OF: So when you went and had your children they tested you
then? 9 years ago.
GX: Oh yeah.

Although the subject had an expectation that she would be tested for HIV, her
response to the issue of mandatory versus voluntary testing was that reflected by
most participants.

GX: I say it should be required. I don’t like that word, “the law”,
because the law, it sounds so demanding. See I still believe in
pro choice, you know. Everybody should have their own
choice.

In response to disagreement with mandatory testing, participants reacted with a
sense of rebellion towards the law. Agreement with this belief was similar with
respect to gender. D.X., an HIV negative male expressed,

If you say it’s the law, I have to do it. It’s like you’re telling me
what to do, like I have to do it. I’ll just tell you no just to be
rebellious.

E.X., a 60 year old female who disclosed that she had been positive for 23 years,
discussed the difference in mechanism of being asked to test would have on her
willingness to comply.
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me go on my time, I'll jump with a quickness. But don’t tell me
what you’ve gotta do cuz the law says.

However, she also stipulates situations that would make it suitable for HIV testing
to be a law. EX, in additions to others in all focus groups, agreed that certain
groups, such as women with high risk lifestyles (commercial sex workers and
active heavy drug users) they may not have the capacity to make a sound testing
decision. They therefore expressed belief in the necessary institution of
mandatory testing in these special circumstances.

OF: Okay, so when it comes to pregnant women, is it okay for
us to tell them that it’s the law?
EX: It depends on how old they are....the older ones can
make up their minds a little better. But these young ones, they
are gonna dodge. Afraid of they boyfriends, and family, to get
knocked down with ridicule. Talk to a young girl, but still you
have to make them.
JS (HIV negative male): Definitely, definitely, cuz lets say like
you have the woman still running the streets doing drugs and
alcohol. They don’t have time to sit down and really take care
of their selves, so it should be mandatory definitely. You gotta
worry about the baby, I know a few pregnant women who they
don’t even care about their self. So they can’t care about their
baby.

P.X., an HIV negative female without children felt that refusal to assent to testing
was associated with a higher likelihood of actually having HIV.

Especially if the lady tells you, “you’re not gonna test my kid”.
Why would they tell you not to? Why would I not want my kids
to be right? That brings your antennas up then. That’s
something to think about. Why would somebody not want to
know if there’s something wrong.
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Many were able to concede that if given the choice, themselves and most
women would consent to testing for the safety of the child. Some participants felt,
therefore, that another exception to allowing mandatory testing in pregnant
women should be for the sake of the unborn child. All of the women in our HIVinfected groups had children, none of whom were HIV-infected. M.X., an HIVinfected female with 6 children, was known to have HIV when her last 2 children
were born. Here, she expresses her belief that she would compromise herself
(and as she believes, would all women in general) for the sake of the child.
MX: I’m saying that most people would think selfishly, but
when it has do with another person, another human being,
your child now…You love this child, and you want this child
you want to know this child is gonna be alright. So therefore,
you’re gonna take the test. You’re gonna want to take this
test. For me, myself, regardless of whether they say that it is
mandatory or not, if they say do you want to take the test, I
would say yes because they (the child) deserve a chance for
life….…and you wanna know cuz there is something you
could prevent.

Attitudes Toward Testing in Newborns
Support of mandatory testing of newborns was unanimous. Participants
felt that even in the absence of parental consent, if the mother had not been
tested then the newborn should be. Central themes in support of this were the
ideas of innocence and helplessness in the unborn child. In addition, participants
cited that the baby would deserve the best chances at attaining a healthy life.
P.W., an HIV negative female with no children, evaluated the benefits of
testing the newborn to both newborns and society.
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PW: I think it’s beneficial for everybody. I mean children don’t
have a choice in the world. They don’t have a choice to be
born to this disease. They clueless, you know. They don’t
have a choice. I think, yeah they should be tested. We talking
about babies, here, a life that’s born into this world clueless.

J.S., also spoke of his reasons for supporting mandatory testing in newborns.

….because of the baby. With me it’s just me, you know. So if I
choose not to have it, I’m just speaking for me. I’m not hurting
anyone but myself. And that’s a decision that I make; when I
make a decision for more than one person, you can almost
say that’s like murder, you know what I mean? In a way, you
know what I mean? Like neglected homicide, or something.
But if it’s just me, then I should suffer for it, then that is me.
But when you gotta be concerned about taking another life
involved you gotta answer for that life too.

Attitudes Towards Prenatal Care
When asked about attendance at prenatal care should HIV testing
become mandatory, most women agreed that they personally would not be
deterred. Both genders, however, were able to cite various reasons that other
women may avoid prenatal care, including high risk lifestyles such as drug
addiction. Other reasons included being a commercial sex worker, fear of
stigmatization by both society and (exacerbation of mistrust) from healthcare
providers. Similar to attitudes regarding testing women, with regards to the
effects of addiction, prostitution, and other high risk behaviors, participants felt
that women in these categories would not have sufficient control over their
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positive were also felt to represent important deterrents to prenatal care.
OF: Do you think that pregnant women would avoid coming to
get their prenatal care if they had to get the HIV test?
PW: It depends. When a person feels you are making them do
something, a lot of people rebel. A lot of women will neglect
prenatal care because of that.
PX: Right. There’s some of us that…I would want to know. But
heaven forbid if she’s an addict and she’s out here ripping and
running and it’s a law. Heaven forbid if she’s got a warrant
somewhere. First thing we think is, that’s a setup. I’m going to
jail. Now they then set me up. I ain’t going down there so they
can lock me up. That’s how we think. A lot of us will not take
the time and get prenatal care if it’s changed to a law.

Health Care Experiences and Attitudes
Another theme during the focus groups was negative experiences with
healthcare. In all sessions, participants spoke at great length with regards to
persistent stigma surrounding drug use in the context of and as a barrier to
attaining health care. In group 1, with HIV uninfected males, there was large
agreement and sharing of experiences.

DX: Exactly, I just had a back operation, and they wouldn’t
give me anything for the pain cuz they knew I was in the
methadone program. And they still won’t….. I mean it hurts
but I’m not gonna be in pain for like a year and a half and
them not give me anything for it cuz I’m in the methadone
program. And that is what they said. (agreement in the
background)
OF: So do you think that they were doing that because they
don’t trust you?
DX: Yeah because I’m a drug addict, yeah, definitely. They
told me that, yeah.
JX: About 6 weeks ago, I was in a car accident. So right away
I told them that I was on the methadone program, that I
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that it was like night and day the way she treated me. I was
like a piece of you know what.
JX: Yeah, after that she is asking me personal questions, like
“oh yeah, how many milligrams are you on. 90 milligrams ,
whoa! And then she asked me what were you using and I
didn’t even answer her. It’s like very stigmatizing.
NX: That’s part of what I had noticed. I don’t like to go to the
doctor and they ask me “are you taking any medications?” …..
So I say yes, I’m on methadone. And they treat you different.
It’s like you don’t have the right to be a good person.
JS: Like a second class citizen.
NX: Yeah, like you don’t have the right to be a good person
just because you made a mistake when you were young using
drugs.
DX: See some people see it like you’re an addict and….
NX: You’re never gonna change.
DX: See methadone is your medicine, just like a diabetic
takes insulin.

While most spoke about drug use, negative experiences related to HIV
status and race were also discussed. P.W. told of the burden of multiple
stigmatizations that effected her willingness to pursue (and therefore access) to
care.

PW: It’s true. We all prejudge and we all stereotype. Me, I
already got three strikes against me because I’m black, I’m a
woman, and I’m a lesbian. And then to be a drug user.

With regards to HIV status and treatment by health care providers, though
negative experiences continue to occur, some were able to cite progress on the
part of healthcare providers in dealing with people infected with HIV.

MX: Until that person’s status is known, you would be
surprised how many people would change in a heartbeat. I’ve
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organization) kudos though. This organization, in the 10 years
or so that I’ve been associated with it, its been far and few
between that people have come in from the outside, like yall
for example. I’ve had nothing but good experiences. ... I really
have found that people have treated me just like a normal
human being, like they would treat their own.
JH: Has it been more with your HIV status that you feel
stigmatized than your drug use?
JR: Yes, I feel it’s more with my HIV status. I would say. Not
with the…I felt more stigmatized with my HIV.
OF: Was he scared about the drugs or the HIV?
JN: I guess because of the HIV.
EX: I guess because of the HIV. Because I had been with this
doctor all the time.
JH: And he knew about your drug use?
EX: Well no. He didn’t know about the drugs. He knew I was
HIV positive. And then he sent me to another doctor.
MX: So yes it has happened a few times. But it’s not as bad
as I feel that it used to be.
JH: So you feel that physicians and nurses are becoming less
judgmental about drug users?
MX: Less judgmental, yes, I think so. And they are getting
better with the HIV. But the people I’ve worked with my HIV
status and I have really no complaints at all because they
have treated me with the utmost respect. I’m very glad that
they are around. I can talk to them and I feel comfortable with
them.

As HIV became more prevalent, clinics and hospitals moved towards more
specialized care. M.T., an HIV-infected female commented on this and its relation
to her satisfaction with her healthcare.

MT: That’s why I have nothing bad to say about 9-5 {an HIV
floor at the local hospital} because the doctors and the nurses
they want to work there. They ask to work there.
OF: That’s the HIV floor.
DX: They are beautiful people.
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V. DISCUSSION
Our study finds that the majority of injecting and non-injecting drug users,
regardless of HIV testing status, believe that pregnant women should be tested
for HIV. Based on our cohort and focus group data, we find that most favor
voluntary testing. Overwhelmingly, our patients emphasize the ability to give
consent. Our finding is consistent with that of others (37) indicating that most
women were concerned with the need to maintain voluntary choice as well as
being aware of HIV status for the sake of their children. Pregnant women have
expressed concerns that women may be being tested without knowledge and
having received information about HIV testing and infection (38). This further
emphasizes the role of informed consent and it’s value to patients. As the
method of prenatal screening currently in place in the state of Connecticut is
voluntary testing with informed consent (an opt-in process), we find this
information to be relevant. The association between having been tested in the
past for HIV (regardless of infection) and agreement with voluntary testing is
reassuring. This may suggest that those who have actually been exposed to the
counseling and testing process do not find it to be bothersome, thereby leading
them to recommend it as a standard of care.
Voluntary, ‘opt in’ testing has led to improved testing rates in both New
York and Connecticut (39, 40); there is, however, room for progress before these
numbers reach 100%, as would likely be seen with mandatory testing. In
Connecticut, having the safety nets of both opt-out testing at delivery and
newborn screening is designed to not miss any cases of HIV in pregnant women
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screening from ‘opt –in’ in Connecticut’s correctional system to be a reduction of
only one infection every 21.5 years. This small benefit is in fact due to the relative
success of voluntary (opt–in) prenatal testing partnered with mandatory newborn
screening. In fact, another important conclusion was that routine (opt-out)
prenatal screening would be highly more effective only in places where no
program or only voluntary screening is in place. This seems to argue against
the need for a more aggressive screening program in the state of Connecticut.
These findings, coupled with the acceptance of voluntary prenatal screening,
suggest that voluntary prenatal screening should be continued in the state of
Connecticut. It is likely then, that more focus should be on optimizing strategies
to obtain consent during prenatal counseling. In addition, our data suggests that
even when presented with a choice at delivery that mostly all women would
consent to testing if such consent is sought. We believe that by optimizing
prenatal testing, the need for the safety net at delivery will be lessened.
In spite of overwhelming support for voluntary testing, focus group
participants identified only one subgroup of women who were not felt to be willing
to provide informed consent, thereby necessitating a mandatory law. These
individuals were described as the young women who were commercial sex
workers and active drug users – groups at highest risk for HIV infection. This
belief highlights an important concern. To bolster the argument in support of
voluntary testing, focus group participants first cited the belief that mostly all
competent women would consent to prenatal testing in concern for the best
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mentioned groups to be unable to maintain control of her own actions for the best
interest of her child, necessitating mandatory testing. By examination of the
inclusion criteria, we note that every single participant in our study at one time
belonged to at least one of the groups felt to need mandatory testing. This is a
well-documented phenomenon of discrimination, especially racism. Brown
described ‘internalized oppression’ in 1986. Internalized oppression is a process
by which a member of an oppressed or stigmatized group will internalize all or
part of the negative stereotypes and expectations held by their culture regarding
his group (41). Similar ideas of this phenomenon have been described in
oppressed groups such as racial minorities (42) and homosexuals. Similarly,
internalized homophobia is described as a self loathing and fear felt when in
close proximity with others because of their sexuality. Internalized homophobia
has been shown to be associated with higher risk sexual behavior and problems
with drug use in gay men (43). Therefore, in order to address these maladaptive
behaviors, this would suggest that more work is needed in breaking down the
oppressive barriers facing gay men and drug users.
Considerable time was devoted to discussing discrimination experienced
from healthcare providers due to drug use and HIV. This is best represented in
the statement from NX, speaking about his being treated as a second class
citizen due to drug use: “Yeah, like you don’t have the right to be a good person
just because you made a mistake when you were using drugs.” Similar ideas
have been published in literature on attitudes towards drug treatment. The self
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shown to be borne out of a feeling that while providers don’t expect a drug user
to overcome addiction, many users agree and are able to cite many instances of
personal and observed failure as corroboration (44). These ideas are at the
essence of this belief in our groups, where instances of perceived discrimination
were discussed at great length.
Though our focus groups were not designed to test the correlation of
internalized oppression with attitudes towards HIV testing, this is not a surprising
finding. Though this belief in our study was cited by both men and women, the
unique issues of oppression in women warrant some attention. The dynamics of
oppression often impede a woman’s ability to negotiate sex and reduce risk for
HIV, especially in people of lower socioeconomic status and minorities. Several
studies have suggested that women who may feel at risk for HIV with their
partners in their relationships may not vocalize this or attempt to negotiate during
sexual encounters. They suggest a correlation with fear of partner violence,
socialization of passive feminine gender roles, and fear of losing mates when
there is a belief that there is a shortage of suitable male partners (45, 46).
Therefore, it may not be that public education messages regarding HIV
prevention are not effective. Internalized oppression in women is likely one of
many factors contributing to minority women accounting for the disproportionate
current rates of HIV infection in women in the United States. This issue must be
further addressed in our society before real progress can be made. In
developing countries where women do not have the status that American women
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effort.
Notwithstanding, here we found ideas consistent with internalized
oppression amongst our drug using men and women. This begs the question of
whether or not our groups truly do not accept mandatory HIV testing laws for
newborns and the current testing laws for pregnant women. Their accepted
position as “victims” of the healthcare system may render them unable to truly
voice their dissension. In fact, they may have come to expect and feel that laws
regulating their actions are necessary. A study in which an index of oppression
was measured by inclusion in some of the above mentioned categories and their
relations to attitudes on HIV testing policies for newborns and pregnant women
would reliably give us this information. These findings do not, in and of itself,
warrant a policy change towards mandatory testing of pregnant women. More
importantly, perhaps, they provide some direction as to which groups may need
to be more closely targeted with regards to the message of HIV testing during
prenatal care.
In the past, it has been shown that women with high risk sexual behaviors,
prostitutes, and women who share needles may have a low level of perceived
risk despite full knowledge of HIV risk factors (47). This would lead credence to
the beliefs amongst our focus group subjects that the high risk women have the
poorest insight into their personal behaviors and lend credence to their beliefs
that they should be subject to mandatory testing.
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cohort populations were not uniform. Over 80% of survey subjects believed that
all newborns should undergo HIV testing. Of those, approximately 60%
advocated testing in the absence of maternal consent. This is consistent with the
definition of mandatory newborn screening. Surprisingly, approximately 14% of
those surveyed did not support testing of all newborns, though not statistically
significant. In the focus groups, however, most believed that the overall safety of
the child should supersede the mother’s decision making. They almost
unanimously supported mandatory newborn testing. The discrepancy in beliefs
between the longitudinal sample and focus groups may be due to an increased
support for mandatory newborn testing after years of implementation of this law
had produced positive results. As the focus of the epidemic continues to stress
prevention, mandatory newborn screening may be becoming less alienating and
more acceptable in certain settings. A salient belief was that most women would
agree to test primarily for the well being of her child, thus eventually negating the
need for it to be mandatory. We found this to be consistent with previous studies
where women, regardless of drug using status, reported concern for baby as
being a large motivation for undergoing HIV testing (48,49).
Here we found that since implementation of the law, the affected patient
population supports mandatory newborn screening. It is important that
mandatory newborn screening is shown to be acceptable. The main factors that
may be deterring states other than New York and Connecticut from implementing
mandatory newborn screening may be ethics and acceptability, cost-
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effective alone when compared with no screening (18). In addition, the authors
found that mandatory newborn screening leads to decreased MTCT even when
there is a successful prenatal screening process. These findings may be
interpreted to suggest that newborn screening may pose fewer barriers to
adaptation in other states, with or without prior screening policies in place.
Conversely, if most women would agree to newborn testing even if it was not the
law, some would question the risk of violating the will of the small few with the
threat of perceived coercion. We found that even though women may be testing
to avoid their newborns being tested, this is their choice and may not represent
coercion. Secondly, there is already a highly effective method of screening in
place in our state. Instead of focusing on policy change, effort would be better
spent elsewhere, such as assuring that women in high risk groups are always
receiving prenatal care.
The majority of women in both samples felt that mandatory HIV testing of
pregnant women would not deter pregnant women from prenatal care. This is
con
sistent with studies by the Perinatal Guidelines Evaluation Project Group.
They have shown that factors facilitating prenatal care in pregnant women often
include prevention of vertical transmission and concern for the well being of other
family members (50). A statistically significant minority of IDU’s (16.2%) said they
would avoid prenatal care if HIV testing was the law. Though no one in the focus
groups voiced this opinion for their personal behavior, there was the belief that
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focus groups participants toward young women, active drug users, and
commercial sex workers. We also believe that the difference in opinion between
the focus groups and the cohort sample can be explained by the temporal
relationship between the two.
Although mandatory HIV testing of pregnant women is not the law in the
state of Connecticut and our findings suggest that most women do not support it,
it is reassuring that none of our focus groups subjects feel it would be a
deterrent. IDU’s have historically had lower rates of attending prenatal care. Due
to needle usage being a more stigmatizing form of drug use, they may have been
more likely to be further displaced by mandatory testing .While we expect to find
no change, formal studies are needed to show if there have been changes in
prenatal care utilization post implementation of the mandatory testing law for
newborns in the state of Connecticut.
Patients continue to feel discriminated against due to their drug use and
HIV status. Many in our study felt, however that major improvements have
occurred surrounding the latter. Our cohorts illustrate the fact that patients
believe that certain people receive better treatment than others in the healthcare
system. With respect to drug use, many described instances of being denied
adequate analgesia by their physicians, being denied care, and being
disrespected by other healthcare providers. In our focus groups, many told
stories of nurses and physicians attitudes towards them changing once their drug
using status was disclosed. Similarly in our cohorts, approximately 26% of
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they did not receive care equal in quality to that of non-drug users. This
continues a history of some distrust in disenfranchised groups due to well studied
physician bias and discrimination (51,52). The negative experiences of drug
users with the health care environment has been reported previously but is
echoed in both the cohort and focus group findings (53,54,55). These negative
experiences with and attitudes toward the healthcare system are likely to result in
poor health outcomes for drug users. They may not, however, ultimately
influence outcomes for HIV testing of pregnant women and newborns. It would,
however, strongly encourage changes in the delivery of health care toward this
population. In order to further explore this issue, focus groups with healthcare
providers from local Connecticut sites would be needed.
Our study has several limitations. Our focus groups were small, and were
recruited by counselors at drug treatment centers. They therefore may not
represent the general drug using population. This may explain the difference in
support of newborn and prenatal screening laws versus the larger longitudinal
sample. Second, all participants were either in treatment or at least in good
standing with their treatment institutions, and therefore may have also been less
likely to disagree with institutional regulations. We believe that this has a very
small contribution towards attitudes, as instances of perceived discrimination and
rebellion against institutions were discussed at great length. Another limitation of
focus groups is that subjects may have been less likely to express dissenting
opinions in the presence of other members. Lastly, the development of themes to
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may have neglected other aspects on the issue of prenatal and newborn
screening that participants wanted to discuss.
To avoid confusion over the language used in our focus groups, the
difference between ‘required’ testing versus ‘the law (mandatory)’ was discussed
in great detail. For our purposes, required was synonymous with what is defined
as a routine testing strategy. We did not however, discuss the real difference in
consent process between routine and voluntary testing, as it has been defined, to
allow participants to draw their own conclusions regarding which consent process
was more acceptable leading them to choosing between one versus the other.
We based this decision on studies that have shown that patients and providers
often differ in perception of information given during prenatal counseling. Others
have illustrated that even when providers inform women that testing is routine,
she may not realize that she has the right to refuse testing (22). Whether or not
this distinction is made and fully understood in clinical practice is important as
even now women may be undergoing testing without full knowledge of the
process in place and their rights.
More than ten years following the publishing of ACTG 076 and
subsequent implementation of more aggressive HIV testing strategies, the U.S.
moves closer to eliminating AIDS in infants(56). Debate continues, however,
regarding ethics and legality of HIV testing programs. In conclusion, we found
that implementation of mandatory testing of newborns and universal, voluntary
testing of pregnant women is largely accepted in the drug using patient

- 33 population. Pregnant women prefer choice with regards to testing. Our work
suggests that most women would assent when counseled regarding the
overarching benefits to the unborn child. As some women would avoid prenatal
care if HIV testing for women was made mandatory, we strongly discourage
consideration of a move towards this policy. Health care providers should
recognize that there will always be exceptions and seek ways to target women in
special situations as well.
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Table 1.
Characteristics
Age
17 to 34 years
35 to 39 years
40 to 44 years
45 to 64 years
Gender
Male
Female
Race
White
Black/African American
Hispanic
Other
Highest level of education
Elementary
Some high school
High school graduate/GED
Some college or higher
Currently employed
No
Yes
HIV testing
Never had a HIV test
Tested negative for HIV
Tested positive for HIV
Regular health care provider
No
Yes
Received public assistance/ public medical insurance in last 6
months
No
Yes
Medicaid/Medicare coverage in last 6 months
No
Yes

n(%)*
160 (26.2)
166 (27.2)
154 (25.3)
127 (20.8)
371 (60.8)
238 (39.0)
204 (33.4)
289 (47.4)
81 (13.3)
32 (5.3)
47 (7.7)
182 (29.8)
247 (40.5)
131 (21.5)
492 (80.7)
111 (18.2)
69 (11.3)
389 (63.8)
137 (22.5)
323 (53.0)
283 (46.4)

147 (24.1)
458 (75.1)
285 (46.7)
317 (52.0)

* Numbers may not add up to totals due to missing data. Percents may not add up to
totals due to rounding.
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Table 2.
Non-Injecting

Injecting

Drug Users
Characteristic

Drug Users

(n=234)

(n=376)
N (%)

p-value

Men and Women (N=610):
Pregnant women should
undergo HIV testing
No
Yes

21 (9.1)

33 (8.9)

209 (90.9)

337 (91.1)

28 (12.3)

55 (15.0)

68 (30.0)

107 (29.1)

131 (57.7)

206 (56.0)

83 (83.8)

123 (93.9)

16 (16.2)

8 (6.1)

0.930

All newborns should undergo
HIV testing
No
Yes, only with mothers’

0.671

consent
Yes, even without mothers’
consent

Women only (n=238):
Avoid prenatal care if a law
required HIV testing in
pregnancy
No
Yes

0.014

Numbers may not add up to totals due to missing data. Percents may not add up to
totals due to rounding.
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Table 3.
Characteristic
Never had a

Prior HIV

HIV test (N=69)

Testing

p-value

(N= 517)
Men and Women (N=586):
Pregnant women should undergo HIV
testing
12 (17.4)

40 (7.7)

57 (82.6)

477(92.9)

10 (14.5)

70 (13.6)

Yes, only with mothers’ consent

18 (26.1)

152 (29.6)

Yes, even without mothers’ consent

41 (59.4)

291 (56.7)

18 (78.3)

183 (90.6)

5 (21.7)

19(9.4)

No
Yes

.008

All newborns should undergo HIV testing
No

.831

Women only (n=238):
Avoid prenatal care if a law required HIV
testing in pregnancy
No
Yes

.144

Numbers may not add up to totals due to missing data. Percents may not add up to
totals due to rounding.
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Table 4.
Characteristic
Mode of drug use
Non-injecting drug users (NIDU)
Injecting drug user (IDU)
Age
17 to 34 years
35 to 39 years
40 to 44 years
45 to 64 years
Gender
Male
Female
Race
White
Black/African American
Hispanic
Other
Highest level of education
Elementary
Some high school
High school graduate/GED
Some college or higher
HIV testing
Never had a HIV test
Tested negative for HIV
Tested positive for HIV
Received public assistance/ public medical insurance in last 6
months
No
Yes
Medicaid/Medicare coverage in last 6 months
No
Yes

Adjusted odds
ratio* (CI)
Referent
1.51 (0.96, 2.38)
Referent
1.17 (0.68, 2.03)
1.16 (0.66, 2.05)
1.65 (0.91, 3.00)
Referent
0.61 (0.40, 0.93)
Referent
1.08 (0.68, 1.72)
0.74 (0.37, 1.46)
1.85 (0.75. 4.54)
1.26 (0.58, 2.73)
1.02 (0.64, 1.63)
Referent
1.08 (0.65, 1.81)
1.24 (0.65, 2.37)
Referent
0.42 (0.25, 0.72)

Referent
1.22 (0.72, 2.06)
Referent
1.06 (0.68, 1.65)

Variables in the table are adjusted for each other. Analysis is valid for subjects
without missing data for variables in the tables.
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Table 5.
Experience/Attitude
A) Related to general health care

N (%)*
No

Yes

326 (59.9)

173 (31.8)

167 (93.8)

10(5.6)

173 (97.2)
177 (99.4)
175 (98.3)
124 (69.7)
131 (73.6)
121 (68.0)

4 (2.3)
0 (0.0)
2 (1.1)
53 (29.8)
46 (25.8)
56 (31.5)

B) Related to drug use (n=499)

Disagree

Agree

Symptoms not taken seriously because s/he is a drug
user
Does not receive as good of care as others because
s/he is a drug user
Provider often suspects that symptoms are related to
drug use
Sees another type of provider instead of a doctor
because s/he is a drug user

353 (64.9)

147 (27.0)

357 (67.2)

134 (25.2)

277 (50.9)

216 (40.6)

401 (73.7)

93 (17.1)

Certain people get better treatment than others (n=531)
The types of people who get better treatment includes
(n=178):
The sickest
People who make appointments
People who just walk in
People who make the most fuss
One particular race/ethnic group
People who do not use drugs
People with private insurance

* Numbers may not add up to totals due to missing data. Percents may not add up to
totals due to rounding.
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Table 6.
Gender
Focus Group

Male

Mode of Drug Use

Female HIV Status

IDU

NIDU

1 (N=5)

5

0

Negative

3

2

2 (N=5)

5

0

Positive

2

3

3 (N=5)

0

5

Positive

0

5

4 (N=5)

0

5

Positive

5

0

5 (N=5)

0

5

Negative

2

3

Total

10

15

12

13
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